Resources
About Us
Home Report
Store
Viral Vaccines Market
Viral Vaccines Market Size, Share, Forecast, & Trends Analysis by Form (Liquid, Lyophilized) Type (Live Attenuated, mRNA, Inactivated) Virus (Adenovirus, Retrovirus, Plasmid DNA, AAV), Approach, Indication, Application, Packaging - Global Forecast to 2031
Report ID:MRHC - 1041237 Pages: 300 Jun-2024 Formats*: PDF Category: Healthcare Delivery: 24 to 72 HoursViral Vaccines Market Size & Forecast
The Viral Vaccines Market is expected to reach $47.01 billion by 2031, at a CAGR of 1.9% from 2024 to 2031. The growth of this market is driven by the increasing government focus on immunization programs, technological advancements in vaccine administration, the use of inactivated vaccines in surgeries or treatment, and the capacity expansion of biopharmaceutical products. Moreover, the growing focus on therapeutic vaccines, the increasing use of adjuvants in vaccines, growth prospects in emerging markets, and the development of highly stable and energy-efficient ultra-low-temperature freezers are expected to offer growth opportunities for the players operating in this market.
Viral Vaccines Market Growth Drivers
Technological Advancements in Vaccine Administration
Vaccine technology has evolved significantly during the last decade, profoundly changing the future of vaccine development. The introduction of genetic engineering has fueled many advancements in vaccine development programs, leading to new products. Various virus vaccines that use the attenuated form of the virus have been developed through these methods. Also, new technologies enable the faster detection of viruses and allow for concentration levels to be kept high enough to generate an immune response.
Recent vaccine technologies are largely driven by the need to accelerate response times against emerging threats and make vaccines available for quick deployment. The increasing need to develop vaccines against difficult targets and improve delivery systems for maximum potency is also the focus of innovation in the vaccine industry. The development of synthetic vaccine candidates, genomic analysis of disease progression and vaccine response, structure-based antigen design, and nanoparticle delivery systems are some of the latest technological advancements in vaccine delivery. Therefore, technological advancements are expected to drive the emergence of new and more effective vaccines for various new indications, fueling the growth of the viral vaccines market.
Click here to: Get Free Sample Pages of this Report
Growing Focus on Therapeutic Vaccines
Although vaccines have historically been intended to prevent diseases, a new category of vaccines known as therapeutic vaccines has emerged recently. Therapeutic vaccines treat diseases by inducing an immune response or strengthening the immune system. Their purpose is to treat patients already affected by the disease. After the launch and success of the first therapeutic vaccine in 2010, key players shifted their focus toward developing an array of therapeutic vaccines for other cancers.
For instance, as of May 2024, Pfizer, Inc. (U.S.) had 17 vaccines in the pipeline that are being researched for diseases and infections such as influenza, hepatitis, Lyme disease, invasive group B streptococcus infection, and respiratory syncytial virus infection. However, therapeutic vaccines currently represent a very small market, limited to vaccines against skin, prostate, and bladder cancers and a few vaccines against pollen allergies; in the future, vaccines for many other indications are expected to reach the market. With market growth expected to be greater than for prophylactic vaccines, therapeutic vaccines hold vast opportunities for vaccine manufacturers.
Viral Vaccines Market Trends
Increasing Preference for Personalized Treatments
Personalized vaccines are the newest advancements that aim to elicit responses against antigens and microorganisms that can be tailored and modified according to the patient's condition, establish durable immunity, and minimize side effects. This personalization can also increase the safety profile and reduce reactogenicity; viral vectors and vaccines can also be genetically modified to make them replication-deficient.
Various vaccines are being developed to counter diseases such as cancers of different types. For instance, in April 2024, according to the American Association for Cancer Research (AACR), researchers reported the development of a new therapeutic cancer vaccine called the TG4050, which can be effective in head and neck squamous cell carcinoma (HNSCC). The TG4050 is an engineered form of the vaccinia virus that delivers 30 personalized neoantigens that are unique to each patient’s tumor and also induces activation of an antitumor immune response.
Media and Public Awareness Regarding Immunization
Public awareness is an important aspect of the sensitization of vaccines and vaccination. Immunization is the process where a person is protected against a disease through vaccination. Immunization can save millions of lives and is considered one of the most successful and cost-effective health interventions. For instance, according to the World Health Organization (WHO), annually, approximately 4-5 million people are saved from several infectious diseases such as hepatitis, tetanus, measles, and polio, among others, due to vaccinations. However, globally, 1.15 million children in the Western Pacific Region do not receive essential vaccinations. Many governments and health organizations are conducting immunization programs to ensure vaccination of people in all parts of the world, including rural areas. For instance, in December 2022, the National Technical Advisory Group for Immunization (NTAGI) (India) recommended introducing the human papillomavirus (HPV) vaccine in the Universal Immunization Programme (UIP) with a one-time catch-up for 9-14-year-old adolescent girls followed by a routine introduction at nine years.
Viral Vaccines Market Opportunity
Growing Focus on Therapeutic Vaccines
Therapeutic vaccines are generally administered after a disease or infection has affected the patient, and they work by activating the immune system of a patient. Therapeutic vaccines are also being majorly used as a viable option for active immunotherapy of cancers. Unlike preventive vaccines, therapeutic vaccines can be customized to respond to specific mutations. These vaccines differ from traditional vaccines as they target the pathogens directly instead of producing antibodies and generating immune proteins. Apart from cancers, therapeutic vaccines can also be used to treat infections resulting from the human papillomavirus (HPV).
Several developments and advancements have taken place recently in vaccine technologies to improve patient immunization. Certain market players are also collaborating to develop new therapeutics for cancer treatment. For instance, in April 2024, CureVac SE (Germany) collaborated with the University of Texas MD Anderson Cancer Center (U.S.) to develop novel mRNA-based cancer vaccines.
Viral Vaccines Market Analysis: Key Findings
By Form: In 2024, the Liquid Vaccines Segment to Dominate the Viral Vaccines Market
Based on form, the market is segmented into liquid vaccines and lyophilized vaccines. In 2024, the liquid vaccines segment is expected to account for the largest share of above 90.3% of the viral vaccines market. Liquid viral vaccines are liquid formulations that contain live and weakened viruses that act as a primary component to induce an immune response in the body and are administered via injections. The large market share of this segment is attributed to factors such as ease of administration, reduced risk of errors, reduced wastage, improved patient experience, low production costs, and better stability. Bharat Biotech Ltd. (India), a vaccines and bio-therapeutics manufacturer, has a live attenuated rotavirus vaccine included in its product portfolio that is a liquid frozen vaccine containing live rotavirus 116E strain and is used for the prevention of rotavirus gastroenteritis.
By Vaccine Type: In 2024, the Subunit & Conjugate Vaccines Segment to Dominate the Viral Vaccines Market
Based on vaccine type, the market is segmented into subunit & conjugate vaccines, live attenuated vaccines, inactivated vaccines, mRNA vaccines, viral vector vaccines, toxoid vaccines, and combination vaccines. In 2024, the subunit & conjugate vaccines segment is expected to account for the largest share of above 51.2% of the viral vaccines market. Subunit vaccines consist of a pathogen fragment, typically a surface protein instead of a whole cell, which is used to trigger an immune response and stimulate acquired immunity against the pathogen. Conjugate vaccines, on the other hand, are similar to recombinant vaccines, which combine two different components from the bacteria coats.
The large market share of this segment is attributed to the vaccines’ long-term immunity, high safety, and stability as compared to vaccines with other antigens. Subunit vaccines also elicit a protective immune response as they do not contain live components and are considered to be more stable than live vaccines. Since the COVID-19 pandemic, the use of subunit and conjugate vaccines has been increasing, which are being used to prevent and treat various diseases and conditions. For instance, in May 2023, GlaxoSmithKline plc (GSK) (U.K.) received the U.S. Food and Drug Administration (FDA) approval for Arexvy, which is a respiratory syncytial virus (RSV) vaccine for older adults. This vaccine is adjuvanted and contains a recombinant subunit prefusion RSV F glycoprotein antigen (RSVPreF3) combined with GSK’s proprietary adjuvant AS01E.
By Virus Type: In 2024, the Adenovirus Segment to Dominate the Viral Vaccines Market
Based on virus type, the market is segmented into adenovirus, retrovirus, plasmid DNA, adeno-associated virus (AAV), lentivirus, and other virus types. In 2024, the adenovirus segment is expected to account for the largest share of the viral vaccines market. Adenoviruses are a group of viruses that can cause mild to severe infections; however, they are used as vectors and actively interact with the innate immune system through various pathways and mechanisms to change the immune environment. The large market share of this segment is attributed to factors such as better stability as compared to other viruses, efficient gene delivery, strong immune response, replication-incompetent viruses, and high scalability. Additionally, adenoviruses have been extensively studied and used in multiple vaccine trials, providing knowledge and experience in their development and optimization for vaccine purposes.
By Approach: In 2024, the Preventive Vaccines Segment to Dominate the Viral Vaccines Market
Based on approach, the market is segmented into preventive vaccines and therapeutic vaccines. In 2024, the preventive vaccines segment is expected to account for the larger share of the viral vaccines market. Preventive vaccines or prophylactic vaccines are designed to prevent diseases before the exposure of pathogens. These vaccines stimulate the immune system to recognize infectious agents and act against them to reduce the incidences and severity of diseases. The large market share of this segment is attributed to the increasing prevalence of chronic and infectious diseases, rising awareness for immunization in public, growing immunization programs, induction of herd immunity, and the prevention of disease outbreaks. For instance, in April 2024, the Pan American Health Organization (PAHO) launched the 22nd edition of Vaccination Week in the Americas (VWA) 2024. This launch also provided updates regarding vaccination coverage and how to take it to the pre-pandemic levels.
However, the therapeutic vaccines segment is expected to register the fastest CAGR during the forecast period. Therapeutic vaccines are given to people who are suffering from infections or diseases to decrease their symptoms. These types of vaccines are mainly used to treat certain kinds of cancers. The fast growth of this segment is attributed to the introduction of antiviral immunity to alter the course of the disease, high specificity and safety, insusceptibility, and low vaccine costs.
By Indication: In 2024, the Infectious Diseases Segment to Dominate the Viral Vaccines Market
Based on indication, the market is segmented into infectious diseases, cancer, genetic disorders, and other indications. In 2024, the infectious diseases segment is expected to account for the largest share of the market. Infectious diseases are conditions that are caused by microorganisms such as bacteria, viruses, fungi, or parasites. Vaccines are regarded as one of the prominent tools to fight infectious diseases. The large share of the segment is attributed to factors such as effectiveness in preventing infectious diseases, faster spread of infectious diseases, and rising risk of pandemics. Viral vaccines for infectious diseases have been used earlier for eradication or near-elimination of diseases such as smallpox and polio in many parts of the world and have significantly reduced the burden of other diseases such as measles, mumps, and rubella.
By Application: In 2024, the Antisense Therapy Segment to Dominate the Viral Vaccines Market
Based on application, the market is segmented into antisense therapy, gene therapy, cell therapy, and vaccinology. In 2024, the antisense therapy segment is expected to account for the largest share of the market. Antisense therapy involves the use of antisense oligonucleotides, which are short synthetic strands of nucleic acids that bind to specific mRNA molecules. Viral vectors are used for this therapy by engineering them to deliver the oligonucleotides encoding antisense RNA into target cells. The large market share of this segment is attributed to the increasing prevalence of diseases such as cancer, genetic disorders, and viral infections, technological advancements in cell & gene therapy, and increasing healthcare expenditure. Rapid development of antisense vaccines is also a key factor supporting the largest share of the market. Antisense vaccines can be developed relatively quickly compared to traditional vaccines. Synthetic nucleic acids can be designed and produced rapidly once the genetic sequence of a pathogen is known, allowing for rapid vaccine development as a response to emerging infectious diseases or pandemics.
Geographical Analysis
By Geography: In 2024, North America to Dominate the Viral Vaccines Market
In 2024, North America is expected to account for the largest share of above 44.0% of the viral vaccines market, followed by Europe, Asia-Pacific, Latin America, and the Middle East & Africa. The large market share of this segment is primarily due to the presence of leading manufacturers, large R&D investments, support from government and regulatory authorities, a rise in the number of infections, the presence of healthcare professionals to administer vaccines, and growing immunization programs for vaccination. In March 2021, Sanofi S.A. (Italy) announced expanding its Canadian footprint with a USD 925 million investment in a new vaccine manufacturing facility in Toronto. The investment was aimed at providing additional antigen and filling capacity for Sanofi’s FLUZONE High-Dose Quadrivalent influenza vaccine to increase the vaccine’s supply in Canada. This facility will also act as an international production and distribution center for Sanofi’s high-dose seasonal influenza vaccine.
However, Asia-Pacific is slated to register the fastest CAGR of above 3.02% during the forecast period. This rapid growth is attributed to an increase in the emergence of infectious diseases, a large population of patients suffering from diseases, rising public awareness for vaccination, and governmental support towards immunization. For instance, in October 2023, the Health Sciences Authority (HSA) of Singapore authorized the updated Spikevax vaccine by Moderna, Inc. (U.S.) to be used in Singapore for the prevention of COVID-19 in individuals aged six months and above. Earlier, in March 2022, the Government of Thailand and the Pediatric Infectious Disease Society of Thailand (PIDST) introduced the Expanded Programme on Immunization (EPI) that has the added inclusions of BCG, HB, DTwP, Hib, OPV, Rota, MMR, Live JE, Influenza, and HPV vaccines for children in the country.
Viral Vaccines Market: Key Companies
The report offers a competitive analysis based on an extensive assessment of the leading players’ product portfolios, geographic presence, and key growth strategies adopted in the last three to four years. Some of the key players operating in the viral vaccines market are Pfizer, Inc. (U.S.), AstraZeneca plc (U.K.), GlaxoSmithKline plc (U.K.), Sanofi S.A. (Italy), CSL Ltd. (Australia), Mitsubishi Tanabe Pharma Corporation (Japan), Merck & Co., Inc. (U.S.), Moderna, Inc. (U.S.), Johnson & Johnson Services, Inc. (U.S.), Dynavax Technologies Corporation (U.S.), Serum Institute of India Pvt. Ltd (India), Emergent BioSolutions, Inc. (U.S.), Bharat Biotech International Limited (BBIL) (India), and Valneva SE (France).
Viral Vaccines Industry Overview: Latest Developments from Key Industry Players
- In March 2024, Cadila Pharmaceuticals (India) launched the Cadiflu Tetra vaccine, which was approved by the Drugs Controller General of India (DCGI) for use in adults and children to protect against the Influenza virus.
- In November 2023, Valneva SE (France) received approval for its single-dose live attenuated IXCHIQ vaccine to prevent the disease caused by the chikungunya virus (CHIKV) in individuals aged 18 years and older.
- In May 2023, the U.S. Food and Drug Administration (FDA) approved GlaxoSmithKline plc’s (U.K.) Arexvy, which is a respiratory syncytial virus (RSV) vaccine for use in the U.S. This is a preventive vaccine used for the prevention of lower respiratory tract diseases caused by RSV in individuals aged 60 years and above.
- In May 2023, the U.S FDA approved ABRYSVO, Pfizer, Inc.’s (U.S.) vaccine for the prevention of RSV in older adults.
Viral Vaccines Market Research Summary
|
Particulars |
Details |
|
Number of Pages |
300 |
|
Format |
|
|
Forecast Period |
2024–2031 |
|
Base Year |
2023 |
|
CAGR (Value) |
1.9% |
|
Market Size (Value) |
USD 47.01 Billion by 2031 |
|
Segments Covered |
By Form
By Vaccine Type
By Virus Type
By Route of Administration
By Approach
By Indication
By Application
By Packaging
|
|
Countries Covered |
North America (U.S., Canada), Europe (Germany, France, U.K., Italy, Spain, Switzerland, Ireland, Denmark, Belgium, Rest of Europe), Asia-Pacific (China, Japan, India, South Korea, and Rest of Asia-Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), and Middle East & Africa |
|
Key Companies |
Pfizer, Inc. (U.S.), AstraZeneca plc (U.K.), GlaxoSmithKline plc (U.K.), Sanofi S.A. (Italy), CSL Ltd. (Australia), Mitsubishi Tanabe Pharma Corporation (Japan), Merck & Co., Inc. (U.S.), Moderna, Inc. (U.S.), Johnson & Johnson Services, Inc. (U.S.), Dynavax Technologies Corporation (U.S.), Serum Institute of India Pvt. Ltd (India), Emergent BioSolutions, Inc. (U.S.), Bharat Biotech International Limited (BBIL) (India), and Valneva SE (France) |
Key questions answered in the viral vaccines market report:
This market study covers the market sizes and forecasts of viral vaccines based on form, vaccine type, virus type, route of administration, approach, indication, application, packaging, and geography. It also provides the value analysis of various segments and sub-segments of the global viral vaccines market at country levels.
The viral vaccines market is projected to reach $47.01 billion by 2031, at a CAGR of 1.9% during the forecast period.
The liquid vaccines segment is expected to account for the largest share of the market in 2024. The large market share of this segment is attributed to factors such as reduced risk of errors, reduced wastage, improved patient experience, low production costs, and better stability.
Among all approaches studied in this report, the therapeutic vaccines segment is slated to register the highest CAGR in the market. The segment's fast growth is attributed to factors such as the introduction of antiviral immunity to alter the course of the disease, high specificity and safety, insusceptibility, and low costs of vaccines.
The growth of the viral vaccines market is driven by several factors, including the increasing government focus on immunization programs, technological advancements in vaccine administration, the use of inactivated vaccines in surgeries or treatment, and the capacity expansion of biopharmaceutical products. Moreover, the growing focus on therapeutic vaccines, increasing use of adjuvants in vaccines, growth prospects in emerging markets, and development of highly stable and energy-efficient ultra-low-temperature freezers are expected to offer growth opportunities for the players operating in this market.
The key players profiled in the viral vaccines market report are Pfizer, Inc. (U.S.), AstraZeneca plc (U.K.), GlaxoSmithKline plc (U.K.), Sanofi S.A. (Italy), CSL Ltd. (Australia), Mitsubishi Tanabe Pharma Corporation (Japan), Merck & Co., Inc. (U.S.), Moderna, Inc. (U.S.), Johnson & Johnson Services, Inc. (U.S.), Dynavax Technologies Corporation (U.S.), Serum Institute of India Pvt. Ltd (India), Emergent BioSolutions, Inc. (U.S.), Bharat Biotech International Limited (BBIL) (India), and Valneva SE (France).
China, Brazil, and India are expected to offer significant growth opportunities for the vendors in this market during the analysis period. This is due to factors such as the rising number of pharmaceutical and biopharmaceutical companies, growing patient population, increasing disposable income, rising awareness of vaccinations, growing immunization programs, and the increasing number of infectious diseases.
1. Introduction
1.1. Market Definition & Scope
1.2. Market Ecosystem
1.3. Currency and Limitations
1.4. Key Stakeholders
2. Research Methodology
2.1. Research Approach
2.2. Process of Data Collection and Validation
2.2.1. Secondary Research
2.2.2. Primary Research/Interviews with Key Opinion Leaders from the Industry
2.3. Market Sizing and Forecast
2.3.1. Market Size Estimation Approach
2.3.2. Growth Forecast Approach
2.3.3. Market Share Analysis
2.4. Assumption for the Study
3. Executive Summary
4. Market Insights
4.1. Overview
4.2. Drivers
4.2.1. Increasing Government Focus on Immunization Programs
4.2.2. Technological Advancements in Vaccine Administration
4.2.3. Use of Inactivated Vaccines in Surgeries or Treatment
4.3. Restraints
4.3.1. High Costs Involved in Vaccine Development
4.3.2. Long Timelines of Vaccine Manufacturing
4.4. Opportunities
4.4.1. Growing Focus on Therapeutic Vaccines
4.4.2. Increasing Use of Adjuvants in Vaccines
4.4.3. Growth Prospects in Emerging Markets
4.4.4. Development of Highly Stable and Energy-efficient Ultra-low Temperature Freezers
4.5. Challenges
4.5.1. Product Recalls
4.5.2. Inadequate Access to Vaccines
4.6. Technology Trends/Market Trends
4.6.1. Increasing Preference for Personalized Treatments
4.6.2. Media and Public Awareness Regarding Immunization
4.7. Regulatory Scenario
4.8. Pricing Analysis
4.9. Parent Market Analysis
4.10. Porter’s Five Forces Analysis
5. Viral Vaccines Market—by Form
5.1. Overview
5.2. Liquid Vaccines
5.3. Lyophilized Vaccines
6. Viral Vaccines Market—by Vaccine Type
6.1. Overview
6.2. Subunit & Conjugate Vaccines
6.3. Live-attenuated Vaccines
6.4. Inactivated Vaccines
6.5. mRNA Vaccines
6.6. Viral Vector Vaccines
6.7. Toxoid Vaccines
6.8. Combination Vaccines
7. Viral Vaccines Market—by Virus Type
7.1. Overview
7.2. Adenovirus
7.3. Retrovirus
7.4. Plasmid DNA
7.5. Adeno-associated Virus (AAV)
7.6. Lentivirus
7.7. Other Virus Types
8. Viral Vaccines Market—by Route of Administration
8.1. Overview
8.2. Intramuscular (IM)
8.3. Subcutaneous (SC)
8.4. Oral
8.5. Other Routes of Administration
9. Viral Vaccines Market—by Approach
9.1. Overview
9.2. Preventive
9.3. Therapeutic
10. Viral Vaccines Market—by Indication
10.1. Overview
10.2. Cancer
10.3. Genetic Disorders
10.4. Infectious Diseases
10.5. Other Indications
11. Viral Vaccines Market—by Application
11.1. Overview
11.2. Antisense Therapy
11.3. Gene Therapy
11.4. Cell Therapy
11.5. Vaccinology
12. Viral Vaccines Market—by Packaging
12.1. Vials
12.2. Prefilled Syringes
13. Viral Vaccines Market—by Geography
13.1. Overview
13.2. North America
13.2.1. U.S.
13.2.2. Canada
13.3. Europe
13.3.1. Germany
13.3.2. France
13.3.3. U.K.
13.3.4. Italy
13.3.5. Spain
13.3.6. Switzerland
13.3.7. Ireland
13.3.8. Denmark
13.3.9. Belgium
13.3.10. Rest of Europe
13.4. Asia-Pacific
13.4.1. Japan
13.4.2. China
13.4.3. India
13.4.4. South Korea
13.4.5. Rest of Asia Pacific
13.5. Latin America
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6. Middle East & Africa
14. Competitive Analysis
14.1. Overview
14.2. Key Growth Strategies
14.3. Competitive Benchmarking
14.4. Competitive Dashboard
14.4.1. Market Leaders
14.4.2. Market Differentiators
14.4.3. Vanguards
14.4.4. Emerging Companies
14.5. Market Share Analysis/ Market Ranking, by Key Players (2023)
15. Company Profiles (Company Overview, Financial Overview, Product Portfolio, Strategic Developments, and SWOT Analysis*)
15.1. Pfizer, Inc.
15.2. AstraZeneca plc
15.3. GlaxoSmithKline plc
15.4. Sanofi S.A.
15.5. CSL Ltd.
15.6. Mitsubishi Tanabe Pharma Corporation
15.7. Merck & Co., Inc.
15.8. Moderna, Inc.
15.9. Johnson & Johnson Services, Inc.
15.10. Dynavax Technologies Corporation
15.11. Serum Institute of India Pvt. Ltd
15.12. Emergent BioSolutions, Inc.
15.13. Bharat Biotech International Limited (BBIL)
15.14. Valneva SE
(Note: SWOT analysis will be provided for the top 5 players only)
16. Appendix
16.1. Available Customization
16.2. Related Reports
List of Tables
Table 1 Global Viral Vaccines Market, by Form, 2022–2031 (USD Million)
Table 2 Global Liquid Vaccines Market, by Country/Region, 2022–2031 (USD Million)
Table 3 Global Lyophilized Vaccines Market, by Country/Region, 2022–2031 (USD Million)
Table 4 Global Viral Vaccines Market, by Vaccine Type, 2022–2031 (USD Million)
Table 5 Global Subunit & Conjugate Viral Vaccines Market, by Country/Region, 2022–2031 (USD Million)
Table 6 Global Live-attenuated Viral Vaccines Market, by Country/Region, 2022–2031 (USD Million)
Table 7 Global Inactivated Viral Vaccines Market, by Country/Region, 2022–2031 (USD Million)
Table 8 Global mRNA Vaccines Market, by Country/Region, 2022–2031 (USD Million)
Table 9 Global Viral Vector Vaccines Market, by Country/Region, 2022–2031 (USD Million)
Table 10 Global Toxoid Viral Vaccines Market, by Country/Region, 2022–2031 (USD Million)
Table 11 Global Combination Viral Vaccines Market, by Country/Region, 2022–2031 (USD Million)
Table 12 Global Viral Vaccines Market, by Virus Type, 2022–2031 (USD Million)
Table 13 Global Adenovirus Vaccines Market, by Country/Region, 2022–2031 (USD Million)
Table 14 Global Retrovirus Vaccines Market, by Country/Region, 2022–2031 (USD Million)
Table 15 Global Plasmid DNA Vaccines Market, by Country/Region, 2022–2031 (USD Million)
Table 16 Global Adeno-associated Virus (AAV) Vaccines Market, by Country/Region, 2022–2031 (USD Million)
Table 17 Global Lentivirus Vaccines Market, by Country/Region, 2022–2031 (USD Million)
Table 18 Global Viral Vaccines Market for Other Virus Types, by Country/Region, 2022–2031 (USD Million)
Table 19 Global Viral Vaccines Market, by Route of Administration, 2022–2031 (USD Million)
Table 20 Global Intramuscular (IM) Viral Vaccines Market, by Country/Region, 2022–2031 (USD Million)
Table 21 Global Subcutaneous (SC) Viral Vaccines Market, by Country/Region, 2022–2031 (USD Million)
Table 22 Global Oral Viral Vaccines Market, by Country/Region, 2022–2031 (USD Million)
Table 23 Global Viral Vaccines Market for Other Routes of Administration, by Country/Region, 2022–2031 (USD Million)
Table 24 Global Viral Vaccines Market, by Approach, 2022–2031 (USD Million)
Table 25 Global Preventive Viral Vaccines Market, by Country/Region, 2022–2031 (USD Million)
Table 26 Global Therapeutic Viral Vaccines Market, by Country/Region, 2022–2031 (USD Million)
Table 27 Global Viral Vaccines Market, by Indication, 2022–2031 (USD Million)
Table 28 Global Viral Vaccines Market for Infectious Diseases, by Country/Region, 2022–2031 (USD Million)
Table 29 Global Viral Vaccines Market for Cancer, by Country/Region, 2022–2031 (USD Million)
Table 30 Global Viral Vaccines Market for Genetic Disorders, by Country/Region, 2022–2031 (USD Million)
Table 31 Global Viral Vaccines Market for Other Indications, by Country/Region, 2022–2031 (USD Million)
Table 32 Global Viral Vaccines Market, by Application, 2022–2031 (USD Million)
Table 33 Global Viral Vaccines Market for Antisense Therapy, by Country/Region, 2022–2031 (USD Million)
Table 34 Global Viral Vaccines Market for Gene Therapy, by Country/Region, 2022–2031 (USD Million)
Table 35 Global Viral Vaccines Market for Cell Therapy, by Country/Region, 2022–2031 (USD Million)
Table 36 Global Viral Vaccines Market for Vaccinology, by Country/Region, 2022–2031 (USD Million)
Table 37 Global Viral Vaccines Market, by Packaging, 2022–2031 (USD Million)
Table 38 Global Viral Vaccine Vials Market, by Country/Region, 2022–2031 (USD Million)
Table 39 Global Prefilled Viral Vaccine Syringes Market, by Country/Region, 2022–2031 (USD Million)
Table 40 Global Viral Vaccines Market, by Country/Region, 2022–2031 (USD Million)
Table 41 North America: Viral Vaccines Market, by Country, 2022–2031 (USD Million)
Table 42 North America: Viral Vaccines Market, by Form, 2022–2031 (USD Million)
Table 43 North America: Viral Vaccines Market, by Vaccine Type, 2022–2031 (USD Million)
Table 44 North America: Viral Vaccines Market, by Virus Type, 2022–2031 (USD Million)
Table 45 North America: Viral Vaccines Market, by Route of Administration, 2022–2031 (USD Million)
Table 46 North America: Viral Vaccines Market, by Approach, 2022–2031 (USD Million)
Table 47 North America: Viral Vaccines Market, by Indication, 2022–2031 (USD Million)
Table 48 North America: Viral Vaccines Market, by Application, 2022–2031 (USD Million)
Table 49 North America: Viral Vaccines Market, by Packaging, 2022–2031 (USD Million)
Table 50 U.S.: Viral Vaccines Market, by Form, 2022–2031 (USD Million)
Table 51 U.S.: Viral Vaccines Market, by Vaccine Type, 2022–2031 (USD Million)
Table 52 U.S.: Viral Vaccines Market, by Virus Type, 2022–2031 (USD Million)
Table 53 U.S.: Viral Vaccines Market, by Route of Administration, 2022–2031 (USD Million)
Table 54 U.S.: Viral Vaccines Market, by Approach, 2022–2031 (USD Million)
Table 55 U.S.: Viral Vaccines Market, by Indication, 2022–2031 (USD Million)
Table 56 U.S.: Viral Vaccines Market, by Application, 2022–2031 (USD Million)
Table 57 U.S.: Viral Vaccines Market, by Packaging, 2022–2031 (USD Million)
Table 58 Canada: Viral Vaccines Market, by Form, 2022–2031 (USD Million)
Table 59 Canada: Viral Vaccines Market, by Vaccine Type, 2022–2031 (USD Million)
Table 60 Canada: Viral Vaccines Market, by Virus Type, 2022–2031 (USD Million)
Table 61 Canada: Viral Vaccines Market, by Route of Administration, 2022–2031 (USD Million)
Table 62 Canada: Viral Vaccines Market, by Approach, 2022–2031 (USD Million)
Table 63 Canada: Viral Vaccines Market, by Indication, 2022–2031 (USD Million)
Table 64 Canada: Viral Vaccines Market, by Application, 2022–2031 (USD Million)
Table 65 Canada: Viral Vaccines Market, by Packaging, 2022–2031 (USD Million)
Table 66 Europe: Viral Vaccines Market, by Country/Region, 2022–2031 (USD Million)
Table 67 Europe: Viral Vaccines Market, by Form, 2022–2031 (USD Million)
Table 68 Europe: Viral Vaccines Market, by Vaccine Type, 2022–2031 (USD Million)
Table 69 Europe: Viral Vaccines Market, by Virus Type, 2022–2031 (USD Million)
Table 70 Europe: Viral Vaccines Market, by Route of Administration, 2022–2031 (USD Million)
Table 71 Europe: Viral Vaccines Market, by Approach, 2022–2031 (USD Million)
Table 72 Europe: Viral Vaccines Market, by Indication, 2022–2031 (USD Million)
Table 73 Europe: Viral Vaccines Market, by Application, 2022–2031 (USD Million)
Table 74 Europe: Viral Vaccines Market, by Packaging, 2022–2031 (USD Million)
Table 75 Germany: Viral Vaccines Market, by Form, 2022–2031 (USD Million)
Table 76 Germany: Viral Vaccines Market, by Vaccine Type, 2022–2031 (USD Million)
Table 77 Germany: Viral Vaccines Market, by Virus Type, 2022–2031 (USD Million)
Table 78 Germany: Viral Vaccines Market, by Route of Administration, 2022–2031 (USD Million)
Table 79 Germany: Viral Vaccines Market, by Approach, 2022–2031 (USD Million)
Table 80 Germany: Viral Vaccines Market, by Indication, 2022–2031 (USD Million)
Table 81 Germany: Viral Vaccines Market, by Application, 2022–2031 (USD Million)
Table 82 Germany: Viral Vaccines Market, by Packaging, 2022–2031 (USD Million)
Table 83 France: Viral Vaccines Market, by Form, 2022–2031 (USD Million)
Table 84 France: Viral Vaccines Market, by Vaccine Type, 2022–2031 (USD Million)
Table 85 France: Viral Vaccines Market, by Virus Type, 2022–2031 (USD Million)
Table 86 France: Viral Vaccines Market, by Route of Administration, 2022–2031 (USD Million)
Table 87 France: Viral Vaccines Market, by Approach, 2022–2031 (USD Million)
Table 88 France: Viral Vaccines Market, by Indication, 2022–2031 (USD Million)
Table 89 France: Viral Vaccines Market, by Application, 2022–2031 (USD Million)
Table 90 France: Viral Vaccines Market, by Packaging, 2022–2031 (USD Million)
Table 91 U.K.: Viral Vaccines Market, by Form, 2022–2031 (USD Million)
Table 92 U.K.: Viral Vaccines Market, by Vaccine Type, 2022–2031 (USD Million)
Table 93 U.K.: Viral Vaccines Market, by Virus Type, 2022–2031 (USD Million)
Table 94 U.K.: Viral Vaccines Market, by Route of Administration, 2022–2031 (USD Million)
Table 95 U.K.: Viral Vaccines Market, by Approach, 2022–2031 (USD Million)
Table 96 U.K.: Viral Vaccines Market, by Indication, 2022–2031 (USD Million)
Table 97 U.K.: Viral Vaccines Market, by Application, 2022–2031 (USD Million)
Table 98 U.K.: Viral Vaccines Market, by Packaging, 2022–2031 (USD Million)
Table 99 Italy: Viral Vaccines Market, by Form, 2022–2031 (USD Million)
Table 100 Italy: Viral Vaccines Market, by Vaccine Type, 2022–2031 (USD Million)
Table 101 Italy: Viral Vaccines Market, by Virus Type, 2022–2031 (USD Million)
Table 102 Italy: Viral Vaccines Market, by Route of Administration, 2022–2031 (USD Million)
Table 103 Italy: Viral Vaccines Market, by Approach, 2022–2031 (USD Million)
Table 104 Italy: Viral Vaccines Market, by Indication, 2022–2031 (USD Million)
Table 105 Italy: Viral Vaccines Market, by Application, 2022–2031 (USD Million)
Table 106 Italy: Viral Vaccines Market, by Packaging, 2022–2031 (USD Million)
Table 107 Spain: Viral Vaccines Market, by Form, 2022–2031 (USD Million)
Table 108 Spain: Viral Vaccines Market, by Vaccine Type, 2022–2031 (USD Million)
Table 109 Spain: Viral Vaccines Market, by Virus Type, 2022–2031 (USD Million)
Table 110 Spain: Viral Vaccines Market, by Route of Administration, 2022–2031 (USD Million)
Table 111 Spain: Viral Vaccines Market, by Approach, 2022–2031 (USD Million)
Table 112 Spain: Viral Vaccines Market, by Indication, 2022–2031 (USD Million)
Table 113 Spain: Viral Vaccines Market, by Application, 2022–2031 (USD Million)
Table 114 Spain: Viral Vaccines Market, by Packaging, 2022–2031 (USD Million)
Table 115 Switzerland: Viral Vaccines Market, by Form, 2022–2031 (USD Million)
Table 116 Switzerland: Viral Vaccines Market, by Vaccine Type, 2022–2031 (USD Million)
Table 117 Switzerland: Viral Vaccines Market, by Virus Type, 2022–2031 (USD Million)
Table 118 Switzerland: Viral Vaccines Market, by Route of Administration, 2022–2031 (USD Million)
Table 119 Switzerland: Viral Vaccines Market, by Approach, 2022–2031 (USD Million)
Table 120 Switzerland: Viral Vaccines Market, by Indication, 2022–2031 (USD Million)
Table 121 Switzerland: Viral Vaccines Market, by Application, 2022–2031 (USD Million)
Table 122 Switzerland: Viral Vaccines Market, by Packaging, 2022–2031 (USD Million)
Table 123 Ireland: Viral Vaccines Market, by Form, 2022–2031 (USD Million)
Table 124 Ireland: Viral Vaccines Market, by Vaccine Type, 2022–2031 (USD Million)
Table 125 Ireland: Viral Vaccines Market, by Virus Type, 2022–2031 (USD Million)
Table 126 Ireland: Viral Vaccines Market, by Route of Administration, 2022–2031 (USD Million)
Table 127 Ireland: Viral Vaccines Market, by Approach, 2022–2031 (USD Million)
Table 128 Ireland: Viral Vaccines Market, by Indication, 2022–2031 (USD Million)
Table 129 Ireland: Viral Vaccines Market, by Application, 2022–2031 (USD Million)
Table 130 Ireland: Viral Vaccines Market, by Packaging, 2022–2031 (USD Million)
Table 131 Denmark: Viral Vaccines Market, by Form, 2022–2031 (USD Million)
Table 132 Denmark: Viral Vaccines Market, by Vaccine Type, 2022–2031 (USD Million)
Table 133 Denmark: Viral Vaccines Market, by Virus Type, 2022–2031 (USD Million)
Table 134 Denmark: Viral Vaccines Market, by Route of Administration, 2022–2031 (USD Million)
Table 135 Denmark: Viral Vaccines Market, by Approach, 2022–2031 (USD Million)
Table 136 Denmark: Viral Vaccines Market, by Indication, 2022–2031 (USD Million)
Table 137 Denmark: Viral Vaccines Market, by Application, 2022–2031 (USD Million)
Table 138 Denmark: Viral Vaccines Market, by Packaging, 2022–2031 (USD Million)
Table 139 Belgium: Viral Vaccines Market, by Form, 2022–2031 (USD Million)
Table 140 Belgium: Viral Vaccines Market, by Vaccine Type, 2022–2031 (USD Million)
Table 141 Belgium: Viral Vaccines Market, by Virus Type, 2022–2031 (USD Million)
Table 142 Belgium: Viral Vaccines Market, by Route of Administration, 2022–2031 (USD Million)
Table 143 Belgium: Viral Vaccines Market, by Approach, 2022–2031 (USD Million)
Table 144 Belgium: Viral Vaccines Market, by Indication, 2022–2031 (USD Million)
Table 145 Belgium: Viral Vaccines Market, by Application, 2022–2031 (USD Million)
Table 146 Belgium: Viral Vaccines Market, by Packaging, 2022–2031 (USD Million)
Table 147 Rest of Europe: Viral Vaccines Market, by Form, 2022–2031 (USD Million)
Table 148 Rest of Europe: Viral Vaccines Market, by Vaccine Type, 2022–2031 (USD Million)
Table 149 Rest of Europe: Viral Vaccines Market, by Virus Type, 2022–2031 (USD Million)
Table 150 Rest of Europe: Viral Vaccines Market, by Route of Administration, 2022–2031 (USD Million)
Table 151 Rest of Europe: Viral Vaccines Market, by Approach, 2022–2031 (USD Million)
Table 152 Rest of Europe: Viral Vaccines Market, by Indication, 2022–2031 (USD Million)
Table 153 Rest of Europe: Viral Vaccines Market, by Application, 2022–2031 (USD Million)
Table 154 Rest of Europe: Viral Vaccines Market, by Packaging, 2022–2031 (USD Million)
Table 155 Asia-Pacific: Viral Vaccines Market, by Country/Region, 2022–2031 (USD Million)
Table 156 Asia-Pacific: Viral Vaccines Market, by Form, 2022–2031 (USD Million)
Table 157 Asia-Pacific: Viral Vaccines Market, by Vaccine Type, 2022–2031 (USD Million)
Table 158 Asia-Pacific: Viral Vaccines Market, by Virus Type, 2022–2031 (USD Million)
Table 159 Asia-Pacific: Viral Vaccines Market, by Route of Administration, 2022–2031 (USD Million)
Table 160 Asia-Pacific: Viral Vaccines Market, by Approach, 2022–2031 (USD Million)
Table 161 Asia-Pacific: Viral Vaccines Market, by Indication, 2022–2031 (USD Million)
Table 162 Asia-Pacific: Viral Vaccines Market, by Application, 2022–2031 (USD Million)
Table 163 Asia-Pacific: Viral Vaccines Market, by Packaging, 2022–2031 (USD Million)
Table 164 China: Viral Vaccines Market, by Form, 2022–2031 (USD Million)
Table 165 China: Viral Vaccines Market, by Vaccine Type, 2022–2031 (USD Million)
Table 166 China: Viral Vaccines Market, by Virus Type, 2022–2031 (USD Million)
Table 167 China: Viral Vaccines Market, by Route of Administration, 2022–2031 (USD Million)
Table 168 China: Viral Vaccines Market, by Approach, 2022–2031 (USD Million)
Table 169 China: Viral Vaccines Market, by Indication, 2022–2031 (USD Million)
Table 170 China: Viral Vaccines Market, by Application, 2022–2031 (USD Million)
Table 171 China: Viral Vaccines Market, by Packaging, 2022–2031 (USD Million)
Table 172 Japan: Viral Vaccines Market, by Form, 2022–2031 (USD Million)
Table 173 Japan: Viral Vaccines Market, by Vaccine Type, 2022–2031 (USD Million)
Table 174 Japan: Viral Vaccines Market, by Virus Type, 2022–2031 (USD Million)
Table 175 Japan: Viral Vaccines Market, by Route of Administration, 2022–2031 (USD Million)
Table 176 Japan: Viral Vaccines Market, by Approach, 2022–2031 (USD Million)
Table 177 Japan: Viral Vaccines Market, by Indication, 2022–2031 (USD Million)
Table 178 Japan: Viral Vaccines Market, by Application, 2022–2031 (USD Million)
Table 179 Japan: Viral Vaccines Market, by Packaging, 2022–2031 (USD Million)
Table 180 India: Viral Vaccines Market, by Form, 2022–2031 (USD Million)
Table 181 India: Viral Vaccines Market, by Vaccine Type, 2022–2031 (USD Million)
Table 182 India: Viral Vaccines Market, by Virus Type, 2022–2031 (USD Million)
Table 183 India: Viral Vaccines Market, by Route of Administration, 2022–2031 (USD Million)
Table 184 India: Viral Vaccines Market, by Approach, 2022–2031 (USD Million)
Table 185 India: Viral Vaccines Market, by Indication, 2022–2031 (USD Million)
Table 186 India: Viral Vaccines Market, by Application, 2022–2031 (USD Million)
Table 187 India: Viral Vaccines Market, by Packaging, 2022–2031 (USD Million)
Table 188 South Korea: Viral Vaccines Market, by Form, 2022–2031 (USD Million)
Table 189 South Korea: Viral Vaccines Market, by Vaccine Type, 2022–2031 (USD Million)
Table 190 South Korea: Viral Vaccines Market, by Virus Type, 2022–2031 (USD Million)
Table 191 South Korea: Viral Vaccines Market, by Route of Administration, 2022–2031 (USD Million)
Table 192 South Korea: Viral Vaccines Market, by Approach, 2022–2031 (USD Million)
Table 193 South Korea: Viral Vaccines Market, by Indication, 2022–2031 (USD Million)
Table 194 South Korea: Viral Vaccines Market, by Application, 2022–2031 (USD Million)
Table 195 South Korea: Viral Vaccines Market, by Packaging, 2022–2031 (USD Million)
Table 196 Rest of Asia-Pacific: Viral Vaccines Market, by Form, 2022–2031 (USD Million)
Table 197 Rest of Asia-Pacific: Viral Vaccines Market, by Vaccine Type, 2022–2031 (USD Million)
Table 198 Rest of Asia-Pacific: Viral Vaccines Market, by Virus Type, 2022–2031 (USD Million)
Table 199 Rest of Asia-Pacific: Viral Vaccines Market, by Route of Administration, 2022–2031 (USD Million)
Table 200 Rest of Asia-Pacific: Viral Vaccines Market, by Approach, 2022–2031 (USD Million)
Table 201 Rest of Asia-Pacific: Viral Vaccines Market, by Indication, 2022–2031 (USD Million)
Table 202 Rest of Asia-Pacific: Viral Vaccines Market, by Application, 2022–2031 (USD Million)
Table 203 Rest of Asia-Pacific: Viral Vaccines Market, by Packaging, 2022–2031 (USD Million)
Table 204 Latin America: Viral Vaccines Market, by Form, 2022–2031 (USD Million)
Table 205 Latin America: Viral Vaccines Market, by Country/Region, 2022–2031 (USD Million)
Table 206 Latin America: Viral Vaccines Market, by Vaccine Type, 2022–2031 (USD Million)
Table 207 Latin America: Viral Vaccines Market, by Virus Type, 2022–2031 (USD Million)
Table 208 Latin America: Viral Vaccines Market, by Route of Administration, 2022–2031 (USD Million)
Table 209 Latin America: Viral Vaccines Market, by Approach, 2022–2031 (USD Million)
Table 210 Latin America: Viral Vaccines Market, by Indication, 2022–2031 (USD Million)
Table 211 Latin America: Viral Vaccines Market, by Application, 2022–2031 (USD Million)
Table 212 Latin America: Viral Vaccines Market, by Packaging, 2022–2031 (USD Million)
Table 213 Brazil: Viral Vaccines Market, by Form, 2022–2031 (USD Million)
Table 214 Brazil: Viral Vaccines Market, by Vaccine Type, 2022–2031 (USD Million)
Table 215 Brazil: Viral Vaccines Market, by Virus Type, 2022–2031 (USD Million)
Table 216 Brazil: Viral Vaccines Market, by Route of Administration, 2022–2031 (USD Million)
Table 217 Brazil: Viral Vaccines Market, by Approach, 2022–2031 (USD Million)
Table 218 Brazil: Viral Vaccines Market, by Indication, 2022–2031 (USD Million)
Table 219 Brazil: Viral Vaccines Market, by Application, 2022–2031 (USD Million)
Table 220 Brazil: Viral Vaccines Market, by Packaging, 2022–2031 (USD Million)
Table 221 Mexico: Viral Vaccines Market, by Form, 2022–2031 (USD Million)
Table 222 Mexico: Viral Vaccines Market, by Vaccine Type, 2022–2031 (USD Million)
Table 223 Mexico: Viral Vaccines Market, by Virus Type, 2022–2031 (USD Million)
Table 224 Mexico: Viral Vaccines Market, by Route of Administration, 2022–2031 (USD Million)
Table 225 Mexico: Viral Vaccines Market, by Approach, 2022–2031 (USD Million)
Table 226 Mexico: Viral Vaccines Market, by Indication, 2022–2031 (USD Million)
Table 227 Mexico: Viral Vaccines Market, by Application, 2022–2031 (USD Million)
Table 228 Mexico: Viral Vaccines Market, by Packaging, 2022–2031 (USD Million)
Table 229 Rest of Latin America: Viral Vaccines Market, by Form, 2022–2031 (USD Million)
Table 230 Rest of Latin America: Viral Vaccines Market, by Vaccine Type, 2022–2031 (USD Million)
Table 231 Rest of Latin America: Viral Vaccines Market, by Virus Type, 2022–2031 (USD Million)
Table 232 Rest of Latin America: Viral Vaccines Market, by Route of Administration, 2022–2031 (USD Million)
Table 233 Rest of Latin America: Viral Vaccines Market, by Approach, 2022–2031 (USD Million)
Table 234 Rest of Latin America: Viral Vaccines Market, by Indication, 2022–2031 (USD Million)
Table 235 Rest of Latin America: Viral Vaccines Market, by Application, 2022–2031 (USD Million)
Table 236 Rest of Latin America: Viral Vaccines Market, by Packaging, 2022–2031 (USD Million)
Table 237 Middle East & Africa: Viral Vaccines Market, by Form, 2022–2031 (USD Million)
Table 238 Middle East & Africa: Viral Vaccines Market, by Vaccine Type, 2022–2031 (USD Million)
Table 239 Middle East & Africa: Viral Vaccines Market, by Virus Type, 2022–2031 (USD Million)
Table 240 Middle East & Africa: Viral Vaccines Market, by Route of Administration, 2022–2031 (USD Million)
Table 241 Middle East & Africa: Viral Vaccines Market, by Approach, 2022–2031 (USD Million)
Table 242 Middle East & Africa: Viral Vaccines Market, by Indication, 2022–2031 (USD Million)
Table 243 Middle East & Africa: Viral Vaccines Market, by Application, 2022–2031 (USD Million)
Table 244 Middle East & Africa: Viral Vaccines Market, by Packaging, 2022–2031 (USD Million)
Table 245 Recent Developments, by Company, 2021–2024
List of Figures
Figure 1 Research Process
Figure 2 Key Secondary Sources
Figure 3 Primary Research Techniques
Figure 4 Key Executives Interviewed
Figure 5 Breakdown of Primary Interviews (Supply-side & Demand-side)
Figure 6 Market Size Estimation
Figure 7 Global Viral Vaccines Market, by Form, 2024 Vs. 2031 (USD Million)
Figure 8 Global Viral Vaccines Market, by Vaccine Type, 2024 Vs. 2031 (USD Million)
Figure 9 Global Viral Vaccines Market, by Virus Type, 2024 Vs. 2031 (USD Million)
Figure 10 Global Viral Vaccines Market, by Route of Administration, 2024 Vs. 2031 (USD Million)
Figure 11 Global Viral Vaccines Market, by Approach, 2024 Vs. 2031 (USD Million)
Figure 12 Global Viral Vaccines Market, by Indication, 2024 Vs. 2031 (USD Million)
Figure 13 Global Viral Vaccines Market, by Application, 2024 Vs. 2031 (USD Million)
Figure 14 Global Viral Vaccines Market, by Packaging, 2024 Vs. 2031 (USD Million)
Figure 15 Global Viral Vaccines Market, by Geography
Figure 16 Global Viral Vaccines Market, by Form, 2024 Vs. 2031 (USD Million)
Figure 17 Global Viral Vaccines Market, by Vaccine Type, 2024 Vs. 2031 (USD Million)
Figure 18 Global Viral Vaccines Market, by Virus Type, 2024 Vs. 2031 (USD Million)
Figure 19 Global Viral Vaccines Market, by Route of Administration, 2024 Vs. 2031 (USD Million)
Figure 20 Global Viral Vaccines Market, by Approach, 2024 Vs. 2031 (USD Million)
Figure 21 Global Viral Vaccines Market, by Indication, 2024 Vs. 2031 (USD Million)
Figure 22 Global Viral Vaccines Market, by Application, 2024 Vs. 2031 (USD Million)
Figure 23 Global Viral Vaccines Market, by Packaging, 2024 Vs. 2031 (USD Million)
Figure 24 Global Viral Vaccines Market, by Geography, 2024 Vs. 2031 (USD Million)
Figure 25 North America: Viral Vaccines Market Snapshot
Figure 26 Europe: Viral Vaccines Market Snapshot
Figure 27 Asia-Pacific: Viral Vaccines Market Snapshot
Figure 28 Latin America: Viral Vaccines Market Snapshot
Figure 29 Key Growth Strategies Adopted by Leading Players, 2021–2024
Figure 30 Global Viral Vaccines Market: Competitive Benchmarking, by Vaccine Type
Figure 31 Global Viral Vaccines Market: Competitive Dashboard
Figure 32 Global Viral Vaccines Market: Market Share Analysis/Market Ranking (2023)
Figure 33 Pfizer, Inc.: Financial Overview (2023)
Figure 34 AstraZeneca plc: Financial Overview (2023)
Figure 35 GlaxoSmithKline plc: Financial Overview (2022)
Figure 36 Sanofi S.A.: Financial Overview (2023)
Figure 37 CSL Ltd.: Financial Overview (2023)
Figure 38 Merck & Co, Inc.: Financial Overview (2023)
Figure 39 Moderna, Inc.: Financial Overview (2023)
Figure 40 Johnson & Johnson Services, Inc.: Financial Overview (2023)
Figure 41 Dynavax Technologies Corporation: Financial Overview (2023)
Figure 42 Emergent BioSolution, Inc.: Financial Overview (2023)
Figure 43 Valneva SE: Financial Overview (2023)
Author Name:
Proudly Partnering With Enterprises Around the Globe
Quick Contact
Related Reports
Veterinary Vaccines Market - Global Opportunity Analysis and Industry Forecast (2024-2030)
Published Date: Jul-2024
Anesthesia Machines Market - Global Opportunity Analysis and Industry Forecast (2024-2030)
Published Date: Jun-2024
Vaccines Market - Global Opportunity Analysis and Industry Forecast (2024-2031)
Published Date: May-2024
Vaccine Storage Equipment Market - Global Opportunity Analysis and Industry Forecast (2020-2027)
Published Date: Jan-2021
